Literature DB >> 20541056

ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas.

Harry Quon, Sue S Yom, Madhur Kumar Garg, Joshua Lawson, Mark W McDonald, John A Ridge, Nabil Saba, Joseph Salama, Richard Smith, Anamaria Reyna Yeung, Jonathan J Beitler.   

Abstract

The optimal management of resectable oropharyngeal squamous cell carcinomas is controversial with many treatment options, both surgical and nonsurgical approaches, supported by published experiences with no randomized trials comparing commonly accepted treatments. The treatment decisions are further complicated by the need for local-regional disease control and competing goals to preserve salivary and swallow function. Treatment decisions may also be affected by tumor and patient related factors and a history of environmental exposure to tobacco and evidence of human papilloma virus. We summarize the published literature and provide treatment consensus derived from the modified Delphi methodology. Copyright 2010 American College of Radiology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20541056     DOI: 10.1016/j.currproblcancer.2010.04.004

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  2 in total

1.  Infrahyoid flap in oropharyngeal reconstruction following carcinoma resection: A study of 6 patients and literature review.

Authors:  Pedro Infante-Cossio; Eduardo Gonzalez-Cardero; Ricardo Lopez-Martos; Victoria Nuñez-Vera; Erika Olmos-Juarez; Alejandro Ruiz-Moya; Juan-Jose Haro-Luna; Eusebio Torres-Carrranza
Journal:  Oncol Lett       Date:  2016-04-07       Impact factor: 2.967

2.  Mini-invasive lateral oropharyngectomy for T3-T4a oropharyngeal cancer.

Authors:  Pierfrancesco Pelliccia; Marcos Martinez Del Pero; Grégoire Mercier; Mohammad Al Felasi; Giorgio Iannetti; Michael Bartolomeo; Marc Makeieff
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-26       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.